Basilea Pharmaceutica
Officials from Basilea Pharmaceutica report latest developments
Published in Physician Business Week, February 13th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Basilea Pharmaceutica.
Report 1: Basilea Pharmaceutica, Ltd., (BSLN) announced the opening of two primary-treatment phase III clinical trials for isavuconazole (BAL8557) in patients with invasive systemic fungal infections caused by yeasts and molds.
Isavuconazole is Basilea's third compound to enter phase III development.
The global trial program for isavuconazole (BAL8557) focuses on patients with invasive candidiasis including candidemia and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Business Week
More Articles from Physician Business Week
- Business Update
Lexmark wins 3-year contract to optimize, manage Health First's printing infrastructure - Personnel
CHF Solutions promotes David B. Springer to president and CEO - Appendicitis
AspenBio Pharma's appendicitis test shows strong early results - Arthritis
Research from University of Los Andes, Department of Medicine provides new data about arthritis - Asthma
Investigators at Center for Urban Epidemiologic Studies have published new data on asthma in children - Asthma Therapy
Recent findings in asthma therapy described by researchers from West Virginia University - More from this issue of Physician Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
